Clinical Trials on Primitive Neuroectodermal Tumors (PNETs)

Total 7318 results

Shenzhen Geno-Immune Medical Institute
Shenzhen Children's Hospital

Recruiting

4SCAR-T Therapy Targeting GD2, PSMA and CD276 for Treating Neuroblastoma

Neuroblastoma

China
Institut Claudius Regaud
Advanced Accelerator Applications

Recruiting

A Clinical Study Evaluating the Safety of Peptide Receptor Radionuclide Therapy (PRRT) With 177Lu-DOTA0-Tyr3-Octreotate in Children With Refractory or Recurrent Neuroblastoma Expressing Somatostatin Receptors. (NEUROBLU 02)

Neuroblastoma

France
Children's Hospital Los Angeles
National Cancer Institute (NCI)

Completed

N2001-02: I-MIBG With Intensive Chemotherapy and Autologous Stem Cell Rescue for High-Risk Neuroblastoma

Neuroblastoma

Canada, United States
New Approaches to Neuroblastoma Therapy Consortium
National Cancer Institute (NCI)

Completed

N2001-03: CEP-701 in Treating Young Patients With Recurrent or Refractory High-Risk Neuroblastoma

Neuroblastoma

United States, Canada
Molecular Insight Pharmaceuticals, Inc.

Completed

N2007-01: Ultratrace™ Iobenguane I 131 in Patients With Relapsed/Refractory High-Risk Neuroblastoma

Neuroblastoma

United States
Burzynski Research Institute

Terminated

Antineoplaston Therapy in Treating Patients With Metastatic, Recurrent, or Refractory Neuroblastoma

Neuroblastoma

United States
Children's Hospital Los Angeles
National Cancer Institute (NCI)

Completed

Chemotherapy in Treating Children With Neuroblastoma

Neuroblastoma

United States
Centre Oscar Lambret
Novartis Pharmaceuticals; National Cancer Institute, France

Completed

Iodobenzylguanidine Meta-I131 and Topotecan in Young Patients With Refractory or Relapsed Metastatic Neuroblastoma (MIITOP)

Neuroblastoma

France
Children's Oncology Group
National Cancer Institute (NCI)

Completed

Studying Biomarkers in Samples From Patients With High-Risk Neuroblastoma

Neuroblastoma
Children's Oncology Group
National Cancer Institute (NCI)

Completed

Gene Expression in Predicting Outcome in Samples From Patients With High-Risk Neuroblastoma

Neuroblastoma
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)

Completed

Iodine I 131 Monoclonal Antibody 3F8 and Bevacizumab in Treating Patients With Relapsed or Refractory Neuroblastoma

Neuroblastoma

United States
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)

Completed

Monoclonal Antibody 3F8 and GM-CSF in Treating Young Patients With High-Risk, Refractory or Relapsed Neuroblastoma

Neuroblastoma

United States
Children's Cancer and Leukaemia Group

Completed

Temozolomide in Treating Young Patients With High-Risk Relapsed or Refractory Neuroblastoma

Neuroblastoma

United Kingdom, Ireland, France
Children's Cancer and Leukaemia Group

Withdrawn

High-Dose Iodine I 131 Metaiodobenzylguanidine, Topotecan, and Peripheral Stem Cell Transplant in Treating Young Patients With Relapsed Stage 4 Neuroblastoma or Primary Resistant High-Risk Neuroblastoma

Neuroblastoma
Memorial Sloan Kettering Cancer Center

Completed

Monoclonal Antibody Therapy Plus Sargramostin in Treating Patients With Advanced Neuroblastoma

Neuroblastoma

United States
New Approaches to Neuroblastoma Therapy Consortium
National Cancer Institute (NCI)

Completed

N99-01: Combination Chemotherapy, Radiation Therapy, and Stem Cell Transplantation in Treating Patients With Neuroblastoma

Neuroblastoma

United States
Gustave Roussy, Cancer Campus, Grand Paris

Recruiting

High-Risk Neuroblastoma Study 2 of SIOP-Europa-Neuroblastoma (SIOPEN) (HR-NBL2)

High-Risk Neuroblastoma

France, Spain, United Kingdom, Norway, Sweden, Finland, Australia, Czechia, Italy, Netherlands, Slovenia, Switzerland, Belgium, Denmark, Greece, Lithuania
University of Texas Southwestern Medical Center

Completed

Pediatric Solid Tumor Metabolism [A Prospective Study Exploring Metabolism of Solid Tumors in Pediatrics]

Sarcoma | Neuroblastoma | Pediatric Cancer

United States
BeiGene

Completed

Evaluation of the Safety and Pharmacokinetics of Dinutuximab Beta as Maintenance Therapy in Chinese Patients With High-risk Neuroblastoma

High-risk Neuroblastoma

China
Memorial Sloan Kettering Cancer Center

No longer available

Naxitamab and GM-CSF in People With Neuroblastoma

High-Risk Neuroblastoma

United States
National Cancer Institute (NCI)

Completed

Monoclonal Antibody Ch14.18, Sargramostim, Aldesleukin, and Isotretinoin After Autologous Stem Cell Transplant in Treating Patients With Neuroblastoma

High Risk Neuroblastoma

United States
United Therapeutics

Terminated

A Study of MAb-3F8 Plus Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) Versus 13-cis-Retinoic Acid (RA) Plus GM-CSF in Primary Refractory Neuroblastoma Patients

Primary Refractory Neuroblastoma

United States
University Hospital, Strasbourg, France

Recruiting

Dinutuximab Beta at the HUS and the Toulouse Oncopole (DNB)

Neuroblastoma

France
Emory University

Recruiting

Allogeneic Expanded Gamma Delta T Cells With GD2 Chemoimmunotherapy in Relapsed or Refractory Neuroblastoma (Aflac-NBL-2002)

Neuroblastoma | Refractory Neuroblastoma | Relapsed Neuroblastoma

United States
Clarity Pharmaceuticals Ltd

Recruiting

67Cu-SARTATE™ Peptide Receptor Radionuclide Therapy Administered to Pediatric Patients With High-Risk, Relapsed, Refractory Neuroblastoma

Neuroblastoma | Refractory Neuroblastoma | Relapsed Neuroblastoma

United States
Children's Hospital Los Angeles
National Cancer Institute (NCI)

Completed

N2004-06: Irinotecan and Vincristine With 131I-MIBG Therapy for Resistant/Relapsed High-Risk Neuroblastoma

Neuroblastoma

United States
Gustave Roussy, Cancer Campus, Grand Paris
National Cancer Institute, France

Terminated

Evaluation of 2 Intensification Treatment Strategies for Neuroblastoma Patients With a Poor Response to Induction (VERITAS)

Very High Risk Neuroblastoma

Italy, Austria, France, Netherlands, Spain
New Approaches to Neuroblastoma Therapy Consortium
National Cancer Institute (NCI)

Completed

N99-02: Melphalan and Buthionine Sulfoximine (BSO)

Neuroblastoma

Canada, United States
New Approaches to Neuroblastoma Therapy Consortium
National Cancer Institute (NCI)

Completed

N2007-03: Vorinostat and 131-I MIBG in Treating Patients With Resistant or Relapsed Neuroblastoma

Neuroblastoma

United States
Nant Operations Center
National Cancer Institute (NCI)

Completed

N2004-03: Intravenous Fenretinide in Treating Young Patients With Recurrent or Resistant Neuroblastoma (IV Fenretinide)

Neuroblastoma

United States, Canada
Columbia University
Instituto de Tratamento do Câncer Infantil

Unknown

Nutritional Status in Neuroblastoma in Sao Paolo, Brazil

Neuroblastoma

Brazil
University of Michigan Rogel Cancer Center
Millennium Pharmaceuticals, Inc.

Completed

Study of Irinotecan and Bortezomib in Children With Recurrent/Refractory Neuroblastoma

Neuroblastoma

United States
Sinobioway Cell Therapy Co., Ltd.
Children's Hospital of Fudan University; Nanjing Children's Hospital

Unknown

Study Evaluating the Efficacy and Safety With CAR-T for Relapsed or Refractory Neuroblastoma in Children

Relapsed or Refractory Neuroblastoma

China
Children's Oncology Group
National Cancer Institute (NCI)

Completed

Biomarkers in Samples From Young Patients With Neuroblastoma

Neuroblastoma
Children's Oncology Group
National Cancer Institute (NCI)

Completed

hu14.18-Interleukin-2 Fusion Protein in Treating Young Patients With Recurrent or Refractory Neuroblastoma

Neuroblastoma

United States, Canada
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)

Completed

Monoclonal Antibody Therapy Plus Etoposide in Treating Patients With Neuroblastoma

Neuroblastoma

United States
Children's Cancer and Leukaemia Group

Unknown

Topotecan, Vincristine, and Doxorubicin in Treating Young Patients With Refractory Stage 4 Neuroblastoma

Neuroblastoma

United Kingdom
Gesellschaft fur Padiatrische Onkologie und Hamatologie...

Unknown

Observation, Combination Chemotherapy, Radiation Therapy, and/or Autologous Stem Cell Transplant in Treating Young Patients With Neuroblastoma

Neuroblastoma

Germany, Switzerland
Memorial Sloan Kettering Cancer Center

Completed

Monoclonal Antibody Therapy in Treating Children With Metastatic Neuroblastoma in Second Remission

Neuroblastoma

United States
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)

Completed

Multiple Therapies in Treating Patients With Advanced Neuroblastoma

Neuroblastoma

United States
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)

Completed

Beta-Glucan and Monoclonal Antibody in Treating Patients With Metastatic Neuroblastoma

Neuroblastoma

United States
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)

Completed

Biological Therapy in Treating Patients With Neuroblastoma That Has Not Responded to Previous Treatment

Neuroblastoma

United States
Children's Hospital Los Angeles
National Cancer Institute (NCI)

Completed

N2000-01: Double Infusion of Iodine I 131 Metaiodobenzylguanidine Followed by Autologous Stem Cell Transplantation

Neuroblastoma

United States
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)

Recruiting

Iodine I 131 Metaiodobenzylguanidine in Treating Patients With Recurrent, Progressive, or Refractory Neuroblastoma or Malignant Pheochromocytoma or Paraganglioma

Neuroblastoma | Pheochromocytoma

United States
University of Texas Southwestern Medical Center

No longer available

131I-Metaiodobenzylguanidine (131I-MIBG) Therapy for Relapsed/Refractory Neuroblastoma

Relapsed Neuroblastoma | Metastatic Pheochromocytoma

United States
Memorial Sloan Kettering Cancer Center

Completed

Anti-GD2 3F8 Antibody and Allogeneic Natural Killer Cells for High-Risk Neuroblastoma

Neuroblastoma | Bone Marrow, Sympathetic Nervous System

United States
Baylor College of Medicine
New Approaches to Neuroblastoma Therapy Consortium

Completed

Zoledronic Acid (ZOMETA) With Cyclophosphamide With Neuroblastoma and Cortical Bone Involvement

NEUROBLASTOMA

United States
Sun Yat-sen University

Recruiting

Apatinib Mesylate Combined With IT Regimen for the Treatment of Recurrent or Refractory Pediatric Neuroblastoma

Neuroblastoma

China
Nationwide Children's Hospital

Recruiting

NK Cells Infusions With Irinotecan, Temozolomide, and Dinutuximab (STING)

Refractory Neuroblastoma | Relapsed Neuroblastoma

United States
National Cancer Institute (NCI)

Active, not recruiting

Dinutuximab, Sargramostim, and Combination Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma

Ganglioneuroblastoma | High Risk Neuroblastoma

United States, New Zealand, Australia

Clinical Trials on Primitive Neuroectodermal Tumors (PNETs)

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Algeria

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations